Seattle Genetics (SGEN +4%) gains despite posting a mixed second quarter. Total revenue surged...

|About: Seattle Genetics, Inc. (SGEN)|By:, SA News Editor

Seattle Genetics (SGEN +4%) gains despite posting a mixed second quarter. Total revenue surged on narrower losses and higher sales of its lymphoma drug Adcetris, but revenue growth still fell short of analyst expectations, largely due to lofty expectations by the Street on Adcetris sales numbers.